<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">While the safety around blood transfusions and invasive medical procedures has improved significantly, injecting drug use remains the main factor fuelling the HCV epidemic in many countries [
 <xref ref-type="bibr" rid="CR1">1</xref>]. The prevalence of HCV infection among people who inject drugs (PWID) ranges from 65% to more than 80% globally [
 <xref ref-type="bibr" rid="CR9">9</xref>]. In high-income countries, 50–80% of new HCV infections are found among PWID [
 <xref ref-type="bibr" rid="CR10">10</xref>]. Yet despite being the population most affected by HCV—and the existence of recommendations for the assessment, management, and treatment of HCV among PWID—their access to screening and treatment remains excessively limited worldwide [
 <xref ref-type="bibr" rid="CR11">11</xref>].
</p>
